Physician profile
Dana Le
NPI 1285030015
$2,969.42
in general payments reported to CMS, 2019-2025
18 companies · $652 in 2025
The $652 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $21.05 · 2021: $134 · 2022: $364 · 2023: $324 · 2024: $655 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $770.69 | 2023-2025 | Rocklatan, Precision 1, Tryptyr |
| Abbvie INC. | $465.48 | 2022-2025 | |
| Allergan, INC. | $443.30 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $354.21 | 2019 | |
| Bausch & Lomb Americas INC. | $160.94 | 2024-2025 | Miebo, Xiidra |
| Glaukos Corporation | $121.36 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $89.53 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $87.16 | 2022-2023 | Cequa |
| Johnson & Johnson Vision Care, INC. | $85.20 | 2021 | |
| Oyster Point Pharma, INC. | $81.75 | 2024 | Tyrvaya |
| Astellas Pharma Global Development | $76.05 | 2024 | Izervay |
| Dompe US, INC. | $64.40 | 2025 | Oxervate |
| Shire North American Group INC | $47.87 | 2019 | |
| Coopervision INC. | $43.71 | 2019 | |
| Thea Pharma INC. | $23.86 | 2025 | Iyuzeh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $23.46 | 2023 | Tecnis Iol |
| Sight Sciences, INC. | $17.49 | 2023 | Tearcare System |
| Horizon Therapeutics Plc | $12.96 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.